Retatrutide dosing typically follows a gradual escalation pattern
The identified proteases responsible for its rapid decay are DPP-4 (dipeptidyl peptidase-4) 34 , which cleaves selectively between residues 2 and 3, and NEP 24.11 35 , which cleaves at multiple sites
Pancreatitis, pancreatic, and thyroid cancer with glucagonlike peptide1based therapies
N Engl J Med (2016) 375:183444
Some of the potential medicines coming down the pipeline include: Survodutide , mazdutide , and pemvidutide , weekly injectable drugs that work on both GLP-1 and glucagon receptors to help reduce weight and lower blood sugar Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon that comes in a once-weekly injection Pramlintide and cagrilintide, injectable drugs that work by acting on receptors for amylin, a hormone produced by the pancreas that plays a role in blood sugar control and satiety (fullness) How long will I take weight loss medications
Common Adverse Effects of GLP-1s The most common adverse effects of GLP-1 receptor antagonists 26 are gastrointestinal-related, including: Nausea Diarrhea Vomiting Constipation Abdominal pain Dyspepsia/indigestion (upset stomach) Nausea is the most common of the GI symptoms, affecting up to 50% of users, but the frequency often gradually reduces as therapy continues
